1. Home
  2. PAXS vs DRUG Comparison

PAXS vs DRUG Comparison

Compare PAXS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Access Income Fund of Beneficial Interest

PAXS

PIMCO Access Income Fund of Beneficial Interest

HOLD

Current Price

$14.72

Market Cap

680.0M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$88.83

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAXS
DRUG
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
680.0M
707.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PAXS
DRUG
Price
$14.72
$88.83
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$129.25
AVG Volume (30 Days)
151.3K
151.6K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.74
$23.18
52 Week High
$16.56
$123.75

Technical Indicators

Market Signals
Indicator
PAXS
DRUG
Relative Strength Index (RSI) 53.87 59.33
Support Level $14.30 $72.06
Resistance Level $14.84 $91.69
Average True Range (ATR) 0.20 4.13
MACD 0.05 0.25
Stochastic Oscillator 69.31 69.87

Price Performance

Historical Comparison
PAXS
DRUG

About PAXS PIMCO Access Income Fund of Beneficial Interest

PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: